

RESULTS OF ANNUAL GENERAL MEETING

Perth, Australia, 14 November 2019: Australian biotechnology company BARD1 Life Sciences Limited (ASX:BD1) (**BARD1 LSL** or the **Company**) advises that all resolutions put to the Annual General Meeting of members today were carried.

In accordance with Listing Rule 3.13.2 and section 251AA(2) of the Corporations Act, the following statistics are provided in respect of each resolution.

Resolution details		Instructions given to validly appointed proxies (as at proxy close)				Number of votes cast on the poll (where applicable)			Resolution Result Carried / Not Carried
Resolution	Resolution Type	For	Against	Proxy's Discretion	Abstain	For	Against	Abstain*	
1 Adoption of Remuneration Report	Ordinary	382,185,305 93.53%	12,810,407 3.13%	13,654,025 3.34%	938,854	Carried on a show of hands			Carried
2 Re-election of Peter Gunzburg as Director	Ordinary	399,585,113 95.36%	663,437 0.16%	18,778,820 4.48%	686,017	Carried on a show of hands			Carried
3 Election of Robert (Max) Johnston as Director	Ordinary	400,348,243 95.41%	500,308 0.12%	18,778,820 4.47%	86,017	Carried on a show of hands			Carried
4 Election of Philip Powell as Director	Ordinary	400,154,807 95.36%	693,745 0.17%	18,778,820 4.47%	86,017	Carried on a show of hands			Carried
5 Ratification of Placement under Listing Rule 7.1 Capacity	Ordinary	194,673,505 84.60%	16,650,297 7.24%	18,778,820 8.16%	7,510,768	Carried on a show of hands			Carried
6 Ratification of Placement under Listing Rule 7.1A Capacity	Ordinary	194,658,506 84.53%	16,865,297 7.32%	18,778,820 8.15%	7,310,768	Carried on a show of hands			Carried
7 Approval of 10% Placement Facility	Special	380,469,817 91.17%	18,053,987 4.33%	18,778,820 4.50%	2,410,768	Carried on a show of hands			Carried
8 Approval of the BARD1 Incentive Option Plan	Ordinary	374,945,188 92.07%	17,491,403 4.30%	14,774,025 3.63%	7,377,982	Carried on a show of hands			Carried
9 Approval of increased remuneration of non-executive Directors	Ordinary	368,614,421 90.72%	18,431,931 4.54%	19,245,765 4.74%	8,296,482	Carried on a show of hands			Carried
10 Modification of Constitution	Special	378,828,268 90.94%	13,365,799 3.21%	24,370,560 5.85%	3,148,768	Carried on a show of hands			Carried

* Votes cast by a person who abstains on an item are not counted in calculating the required majority on a poll.

Pauline Collinson
Company Secretary

ABOUT BARD1 LIFE SCIENCES LTD

BARD1 Life Sciences Ltd (ASX:BD1) is an Australian medical technology company focused on developing and commercialising non-invasive diagnostic tests for early detection of cancer. BARD1 owns a proprietary tumour marker platform with potential diagnostic and therapeutic applications across multiple cancers. The pipeline includes BARD1 autoantibody tests in development for early detection of breast, ovarian and lung cancers. BARD1's mission is to detect cancer earlier and save lives. For more information on BARD1, see www.bard1.com.